...
首页> 外文期刊>Thyroid: official journal of the American Thyroid Association >The importance of age over radioiodine avidity as a prognostic factor in differentiated thyroid carcinoma with distant metastases.
【24h】

The importance of age over radioiodine avidity as a prognostic factor in differentiated thyroid carcinoma with distant metastases.

机译:年龄远高于放射性碘的亲和力作为远处转移的分化型甲状腺癌的预后因素的重要性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Differentiated thyroid carcinoma (DTC) usually has a good prognosis and rarely develops distant metastases. Although it might be expected that avid radioiodine uptake in distant metastases would be associated with a favorable outcome, there are few long-term studies regarding this. The present study was performed to evaluate the influence of radioiodine uptake in distant metastases on the disease-specific survival (DSS) in DTC patients. METHODS: This retrospective study included 77 DTC patients with distant metastases (M1) who were treated with (131)I therapy from 1977 to the end of 2000 in our institution. The median follow-up of patients was 6.1 years. Univariate and multivariate analysis were performed using the Kaplan-Meier method and log rank test, and Cox Regression model, respectively. RESULTS: Seventy-seven patients with M1 included 51 (66.2%) women and 26 (33.8%) men; 32 (41.6%) patients were <45 years old and 45 (58.4%) patients were >or=45 years old (range: 8-70 years; mean age: 45.4 years); histologically, there were 54 (70.1%) papillary carcinomas, 22 (28.6%) follicular carcinomas, and one case (1.3%) with an inconclusive histological report. The probability of DSS after appearance of M1 was 57.95% after 5 years, 48.31% after 10 years, and 39.46% after 15 and 20 years. In patients with iodine-avid distant metastases the 5-year DSS was 66.54%, the 10-year DSS was 55.09%, and the 15- and 20-year DSS were 44.99%. In contrast, patients with non-iodine-avid lesions had a 5- and 10-year DSS of 18.33%. This difference relating to the relationship between (131)I uptake in distant metastases and survival was significant (p = 0.0006). The proportion of patients with non-iodine-avid distant metastases that were >or=45 years old was significantly greater than the proportion of patients with non-iodine-avid distant metastases that were <45 years old (p < 0.01). If patients were matched for age, iodine non-avidity significantly shortened the survival in patients <45 years old (p < 0.001). According to multivariate analysis age had significantly greater influence on survival compared with iodine avidity (p < 0.001, p = 0.078, respectively). CONCLUSION: Patients with distant metastases have a long-term survival that depends, in addition to other factors, on age and the degree of radioiodine uptake in distant metastases.
机译:背景:分化型甲状腺癌(DTC)通常预后良好,很少发生远处转移。尽管可以预期远处转移中大量摄取放射性碘会带来有利的结果,但对此的长期研究很少。进行本研究以评估远处转移中放射性碘的摄取对DTC患者疾病特异性存活率(DSS)的影响。方法:这项回顾性研究纳入了我院自1977年至2000年底接受(131)I治疗的77例DTC远处转移(M1)患者。患者的中位随访时间为6.1年。使用Kaplan-Meier方法和对数秩检验以及Cox回归模型分别进行单变量和多变量分析。结果:77例M1患者包括51名(66.2%)女性和26名(33.8%)男性; <45岁的32名患者(41.6%)和> = 45岁的45名(58.4%)患者(范围:8-70岁;平均年龄:45.4岁);在组织学上,有54例(70.1%)的乳头状癌,22例(28.6%)的滤泡状癌,还有1例(1.3%)的组织学报告尚无定论。 M1出现5年后出现DSS的可能性为57.95%,10年之后为48.31%,15和20年之后为39.46%。碘远距离转移的患者的5年DSS为66.54%,10年DSS为55.09%,而15年和20年DSS为44.99%。相比之下,具有非碘禽类病变的患者的5年和10年DSS为18.33%。与远处转移中的(131)I摄取与生存之间的关系有关的这种差异是显着的(p = 0.0006)。 >或= 45岁的非碘-远距离转移的患者比例明显大于<45岁的非-碘-远距离转移的患者比例(p <0.01)。如果患者的年龄相匹配,则碘不足会显着缩短<45岁患者的生存期(p <0.001)。根据多变量分析,与碘的亲和力相比,年龄对生存的影响显着更大(分别为p <0.001,p = 0.078)。结论:远处转移患者的长期生存除其他因素外,还取决于年龄和远处转移中放射性碘摄入的程度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号